Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 6, 1996, Pages 569-573

  Meenan, John ^a,c   Grool, Tim A ^a   Hommes, Daan W ^a   Dijkhuizen, Sophie ^a   Ten Kate, Fibo J ^a   Wood, Michael ^b   Whittaker, Michael ^b   Tytgat, Guido N ^a   Van Deventer, Sander J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b British Biotechnology   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Colitis; Eicosanoids; Inflammation; Platelet activating factor

Indexed keywords

FORMALDEHYDE; IMMUNOGLOBULIN; LEUKOTRIENE B4; LEXIPAFANT; MYELOPEROXIDASE; N METHYL N [4 [2 METHYL 1H IMIDAZO[4,5 C]PYRIDIN 1 YLMETHYL]PHENYLSULFONYL]LEUCINE ETHYL ESTER; PROSTAGLANDIN E2; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DIALYSATE; IMMUNOGLOBULIN AGGREGATE; MALE; MUCOSA INFLAMMATION; NEUTROPHIL; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; RABBIT;

EID: 8944238477     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199606000-00014     Document Type: Article

References (36)

1. Almer S, Franzen L, Olaison G, Smedh K, Strom M: Phospholipase A2 activity of colonic mucosa in patients with ulcerative colitis. Digestion 1991, 50:135-141.
2. Hawkey CJ: Acute treatment of inflammatory bowel disease, prednisolone: dosage and duration. Netherlands J Med 1989, 35:s21-s26.
3. Prescott SM, Zimmerman GA, McIntyre TM: Platelet activating factor. J Biol Chem 1990, 265:17381-17384.
4. Ferraris L, Karmeli F, Eliakim R, Klein J, Fiocchi C, Rachmilewitz D: Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis. Gut 1993, 34:665-668.
5. Kubes P: Immunopathophysiology of the gastrointestinal tract: role of platelet activating factor. In Immunopharmacology of the Gastrointestinal System. Edited by Wallace JL. London: Academic Press; 1993:105-122.
6. Rosam AC, Wallace JL, Whittle BJR: Potent ulcerogenic actions of platelet activating factor on the stomach. Nature 1986, 319:54-57.
7. Sun X, Hsueh W: Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet activating factor. J Clin Invest 1988, 81:1328-1331.
8. Chung KF: Platelet activating factor in inflammation and pulmonary disorders. Clin Sci 1992, 83:127-138.
9. Eliakim R, Karmeli F, Razin E, Rachmilewitz D: Role of platelet activating factor in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology 1988, 95:1167-1172.
10. Rachmilewitz D, Karmeli F, Eliakim R: Platelet activating factor - a possible mediator in the pathogenesis of ulcerative colitis. Scand J Gastroenterol 1990, 25(s172):19-21.
11. Kald B, Olaison G, Sjodahl R, Tagesson C: Novel aspect of Crohn's disease: increased content of platelet activating factor in ileal and colonic mucosa. Digestion 1990, 46:199-204.
12. Denizot Y, Chaussade S, Nathan N, Colombel JF, Bossant MJ, Cherouki N, et al.: PAF-acether and acetylhydrolase in stool of patients with Crohn's disease. Dig Dis Sci 1992, 37:432-437.
13. Sobhani I, Hochlaf S, Denizot Y, Vissuzaine C, Rene E, Benveniste J, et al.: Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut 1992, 33:1220-1225.
14. Kuijpers TW, Hakkert BC, Hart MHL, Roos D: Neutrophil migration across monolayers of cytokine prestimulated endothelial cells: a role for PAF and IL-8. J Cell Biol 1992, 117:565-572.
15. Braquet P, Touqui L, Shen TY, Vargaftig BB: Perspectives in platelet activating factor research. Pharmacol Rev 1987, 39:97-145.
16. Wallace JL: Release of platelet activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can J Physiol Pharmacol 1988, 66:422-425.
17. Braquet P: Modulation of adhesion molecules by PAF. J Lipid Mediat 1994, 10:75-76.
18. 4 by the human neutrophil when studied in a cell superfusion model. J Immunol 1989, 143:3659-3665.
19. Stewart AG, Dubbin PN, Harris T, Dusting GJ: Platelet activating factor may act as a second messenger in the release of eicosanoids and superoxide anions from leukocytes and endothelial cells. Proc Natl Acad Sci USA 1990, 87:3215-3219.
20. Doebber TW, Wu MS, Mauriello A, Alberts A: Platelet activating factor (PAF) stimulates the lysoPAF acetyltransferase in leukocyte rich plasma: use in PAF antagonist studies. Lipids 1991, 26:997-1003.
21. 4, platelet activating factor and 5-HETE. J Cell Physiol 1985, 122:229-239.
22. Au B, Collins PD, Williams TJ: Role of PAF in zymosan induced IL-8 release from human neutrophils. Agents Actions 1994, 41sC:C185-C187.
23. Deshpande Y, Longo WE, Chandel B, Niehoff M, Robinson S, Polities G, et al.: Effect of platelet activating factor (PAF) and its antagonists on colonic dysmotility and tissue levels of colonic neuropeptides. Gastroenterology 1994, 106:A487.
24. Caplan MS, Hedlund E, Hill N, MacKendrick W: The role of endogenous nitric oxide and platelet activating factor in hypoxia induced intestinal injury in rats. Gastroenterology 1994, 106:346-352.
25. Lambrecht G, Pamham MJ: Kaduserenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes. Br J Pharmacol 1986, 87:287-289.
26. 2+ in human airway epithelial cells. J Biol Chem 1994, 269:4254-4259.
27. Whittaker M, Askew M, Beauchamp CL, Bowles SA, Cackett KS, Campion C, et al.: Structure activity relationships for BB-823 and related PAF antagonists. J Lipid Mediators Cell Signalling 1994, 10:151-152.
28. Thompson WA, Coyle S, van Zee K, Oldenburg H, Trousdale R, Rogy M, et al.: The metabolic effects of platelet activating factor antagonism in endotoxaemic man. Arch Surg 1994, 129:72-79.
29. Kubes P, Ibbotson G, Russell J, Wallace JL, Granger DN: Role of platelet activating factor in ischemia/reperfusion induced leukocyte adherence. Am J Physiol 1990, 22:G300-G305.
30. Liu DL, Jeppsson B, Heuer HO, Hakannsson CH, Svanberg K, Svanberg S, et al.: Beneficial effects of platelet activating factor receptor WEB 217Q on 90 minute hepatic inflow interruption. Eur J Gastroenterol Hepatol 1994, 6:1015-1022.
31. van Haeringen NJ, Verbey NL, van Delft JL: Antagonists and inhibitors of lipid mediators in experimental inflammation of the cornea. J Ocul Pharmacol 1993, 9:365-372.
32. Malchow H, Ewe K, Goebell H, Wellman W, Leimer H, Kempe R: Failure of the specific PAF antagonist apafant in the treatment of ulcerative colitis. Gastroenterology 1994, 106:A728.
33. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 1989, 320:365-376.
34. Teahon K, Bjarnasson I: Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel. Gut 1993, 34:1535-1538.
35. 2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut 1980, 21:591-596.
36. Wallace JL: Eicosanoids. In Inflammatory Bowel Disease: from Bench to Bedside. Edited by Shanahan F, Targan S. Baltimore: Williams and Wilkins; 1994:123-132.